Ocana, A., Gil-Martin, M., Martín, M., Rojo, F., Antolín, S., Guerrero, Á., . . . Urruticoechea, A. (2017). A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. Oncotarget.
Citação norma ChicagoOcana, Alberto, et al. "A Phase I Study of the SRC Kinase Inhibitor Dasatinib With Trastuzumab and Paclitaxel As First Line Therapy for Patients With HER2-overexpressing Advanced Breast Cancer. GEICAM/2010-04 Study." Oncotarget 2017.
MLA citiranjeOcana, Alberto, et al. "A Phase I Study of the SRC Kinase Inhibitor Dasatinib With Trastuzumab and Paclitaxel As First Line Therapy for Patients With HER2-overexpressing Advanced Breast Cancer. GEICAM/2010-04 Study." Oncotarget 2017.